Osteoarthritis

Levolta partners with Tabuk for OA therapy commercialisation in MEA region

Levolta Pharmaceuticals has entered into an exclusive licensing and distribution agreement with Tabuk Pharmaceutical for commercialising VOLT01, an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region.

Abiogen Pharma acquires 97.09% stake in EffRx Pharmaceuticals

Italy-based Abiogen Pharma has announced the acquisition of a 97.09% stake in Switzerland-based EffRx Pharmaceuticals.

FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis

The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis.

Biogen and Bio-Thera Solutions announce commercialisation and license agreement for BAT1806

Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806.

AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of adults with active psoriatic arthritis.

USFDA extends review period for AbbVie’s sNDA of upadacitinib

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.